IMNN - Imunon, Inc.

3.24
-0.100   -3.086%

Share volume: 19,382
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.34
-0.10
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 43%
Dept financing 33%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.52%
1 Month
0   0%
3 Months
-16.92%
6 Months
-44.33%
1 Year
258.01%
2 Year
230.61%
Key data
Stock price
$3.24
P/E Ratio 
0.00
DAY RANGE
$3.15 - $3.55
EPS 
-$3.84
52 WEEK RANGE
$0.37 - $9.42
52 WEEK CHANGE
$264.04
MARKET CAP 
12.934 M
YIELD 
N/A
SHARES OUTSTANDING 
3.070 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$19,110
AVERAGE 30 VOLUME 
$28,183
Company detail
CEO: Corinne L. Goff
Region: US
Website: imunon.com
Employees: 30
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Celsion Corporation focuses on the development and commercialization of DNA-based immunotherapies and vaccines. Its product pipeline includes GEN-1 and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin.

Recent news